Advancing an internal portfolio of novel full human agonist antibodies and novel highly selective ion-channel blockers, Zebra Boilogics is a pre-clinical stage biopharmaceutical company pioneering development of platform technologies to allow cellular function-based screening for the discovery and selection of fully human therapeutic biologics (antibodies, peptides or proteins) from DNA-encoded combinatorial libraries of human antibodies, peptides or âprotein-in-proteinsâ. Zebra Biologics olds an exclusive licenses from the The Scripps Research Institute both to the core platform technology and to current and future candidate therapeutics derived from the platform. Applicable for lead discovery across all therapeutic areas and all receptor classes, Zebra has optimized the platform for the highly desirable feature of allowing selection of rare agonist antibodies from very large combinatorial librari
